ANXA2 and prostate carcinoma: Metastatic prostate cancer cells for example were shown to use CXCR4/CXL12 [183, 184], Annexin II/Annexin II receptor [185] as well as CXCR7 [186] pathways to establish themselves in the bone [187–189].